Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
umostat
- Development stage
- Unknown
- Lead developer
- Yuekang Pharmaceutical Group
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
Umostat (CT102) is a first-in-class antisense oligonucleotide (ASO) developed by Yuekang Pharmaceutical Group. It is designed to specifically target and inhibit the expression of the Insulin-like Growth Factor 1 Receptor (IGF-1R) by binding to its mRNA and promoting its degradation. IGF-1R is a transmembrane tyrosine kinase receptor that is frequently overexpressed in various solid tumors, including pancreatic cancer and hepatocellular carcinoma, where it plays a critical role in tumor cell proliferation, survival, and resistance to apoptosis. By downregulating IGF-1R protein levels, umostat aims to suppress oncogenic signaling pathways and inhibit tumor growth. The drug is currently being evaluated in clinical trials for the treatment of advanced solid tumors, with a particular focus on pancreatic cancer and primary liver cancer.
- Other names
- Umostate优莫司他
02
Targets
IGF-1R (Insulin-like growth factor 1 receptor)
Beyond the preview
Go deeper on umostat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on umostat.